Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-reference, Flexible-dose Study of Brexpiprazole in Patients With Acute Schizophrenia

Trial Profile

Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-reference, Flexible-dose Study of Brexpiprazole in Patients With Acute Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2019

At a glance

  • Drugs Brexpiprazole (Primary) ; Quetiapine
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 01 Jan 2019 Results assessing the effect of the D2-receptor partial agonist brexpiprazole on prolactin, based on pooled data from NCT01396421, NCT01393613, NCT01810380, NCT01397786, NCT01810783, published in the Journal of Clinical Psychopharmacology.
    • 09 Oct 2018 Results (n=541) post-hoc pooled analysis data from three phase 3 trials of this and other 2 trials assessing efficacy of brexpiprazole in Schizophrenic patients with clinically relevant levels of negative symptoms, presented at the 31st Annual Congress of the European College of Neuropsychopharmacology.
    • 17 Feb 2017 According to an Otsuka Pharmaceutical media release, brexpiprazole (Rexulti) has been approved by Health Canada based on data from this and two other phase III trials (700202951 and 700202559).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top